Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Wire Texas.
Press releases published on April 10, 2025
Transcend Biologics Launches TropoVet™ PRP: Advancing Regenerative Care in Veterinary Medicine
EIN Presswire
·
April 10, 2025
Transcend Biologics launches TropoVet™ PRP, a one-step regenerative therapy that enhances healing and recovery for pets using advanced platelet technology. DALLAS, TX, UNITED STATES, April 10, 2025 /EINPresswire.com/ -- Transcend Biologics, a leading …
Bexa™ Project Expands Breast Cancer Screening Access in Rural Texas
EIN Presswire
·
April 10, 2025
LUBBOCK, TEXAS, UNITED STATES, April 10, 2025 /EINPresswire.com/ -- According to the most recent CDC report, more than 42,000 women in the U.S. lost their lives to breast cancer in 2022. Early detection of breast cancer significantly reduces mortality …
Enhancing Lives Through Compassionate Care: TMF Health Quality Institute Contributes to Divine Canines
EIN Presswire
·
April 10, 2025
AUSTIN, TX, UNITED STATES, April 10, 2025 /EINPresswire.com/ -- In March of this year, TMF Health Quality Institute donated $10,000 to Divine Canines, a local nonprofit organization that trains dogs and handlers to provide canine therapy for people in …
DigitalXForce to Launch X-ROC and Cutting-Edge Risk Management Solutions at GISEC, RSA, Blackhat and Gartner Conferences
EIN Presswire
·
April 10, 2025
DigitalXForce to Launch X-ROC and Cutting-Edge Risk Management Solutions at GISEC, RSA, Blackhat and Gartner Conferences DALLAS, TX, UNITED STATES, April 10, 2025 /EINPresswire.com/ -- DigitalXForce, a pioneer in real-time, continuous enterprise …
Immuron Travelan® highest sales in history
GlobeNewswire
·
April 10, 2025
Sales Highlights (unaudited): Global Immuron exceeds AUD$5 million in sales in a fiscal year - highest sales in history March 2025 Quarter AUD$1.3 million up 2% on prior year March 2025 Year to Date AUD$5.3 million up 46% on prior year Australia March 2025 …
argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy
GlobeNewswire
·
April 10, 2025
VYVGART, the first-in-class FcRn blocker, now offers three administration options, including self-injection with a prefilled syringe Self-injection provides gMG and CIDP patients with flexibility for when and where to receive treatment – at home, while ‘on …
Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
April 10, 2025
SAN DIEGO, April 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on April 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of …
Passing of former Chief Executive Officer, Dr. Loressa Cole
GlobeNewswire
·
April 10, 2025
SILVER SPRING, MD, April 10, 2025 (GLOBE NEWSWIRE) -- It is with profound sadness that we share the passing of our former Chief Executive Officer, Loressa Cole, DNP, MBA, RN, NEA-BC, FAAN, FACHE. Loressa was a beloved member of the American Nurses …
Harvard Bioscience Announces CFO Transition
GlobeNewswire
·
April 10, 2025
HOLLISTON, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced the resignation of Jennifer Cote, the Company’s Chief Financial Officer and Treasurer. Ms. Cote’s resignation will be effective …
Odylia Therapeutics drives commitment to rare disease drug development through Rare Disease Day event
GlobeNewswire
·
April 10, 2025
BOSTON, MA, April 10, 2025 (GLOBE NEWSWIRE) -- Odylia Therapeutics (Odylia) a nonprofit biotechnology company dedicated to expediting drug development for rare diseases, hosted a Rare Disease Day event to foster conversations about new funding models and …
Arcutis Announces Chief Financial Officer Transition
GlobeNewswire
·
April 10, 2025
WESTLAKE VILLAGE, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that David Topper, …
BioClick – an enzyme engineering game-changer, launched by eXoZymes and supported by a $300K NIH grant
GlobeNewswire
·
April 10, 2025
Monrovia, CA, April 10, 2025 (GLOBE NEWSWIRE) -- Today, eXoZymes Inc. (NASDAQ: EXOZ) (“eXoZymes”) - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - announced its …
Venus Concept Announces Closing of $1.1 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
GlobeNewswire
·
April 10, 2025
TORONTO, April 10, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced the closing of its previously announced registered direct offering priced at- …
Adaptive Biotechnologies to Report First Quarter 2025 Financial Results on May 1, 2025
GlobeNewswire
·
April 10, 2025
SEATTLE, April 10, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease …
BrightSpring Health Services, Inc. to Announce First Quarter 2025 Financial Results on May 2, 2025
GlobeNewswire
·
April 10, 2025
LOUISVILLE, Ky., April 10, 2025 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG) announced today that it plans to release its first quarter 2025 financial results on Friday, May 2, 2025, prior to the …
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
April 10, 2025
DUBLIN, April 10, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non- …
Protara Therapeutics to Present Interim Analysis from the Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the American Urological Association Annual Meeting
GlobeNewswire
·
April 10, 2025
NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that two presentations and a panel …
Folia Health Expands Its Rare Renal Disease Research with a New C3G Study to Assess Real-World Disease Impact
GlobeNewswire
·
April 10, 2025
BOSTON, April 10, 2025 (GLOBE NEWSWIRE) -- Folia Health launches enrollment for an innovative, at-home real-world evidence initiative for individuals with C3 glomerulopathy (C3G). Designed in partnership with C3G clinicians and patients, this study uses …
PROCEPT BioRobotics® Announces Investor Event at 2025 AUA Annual Meeting at the Aria Resort in Las Vegas
GlobeNewswire
·
April 10, 2025
SAN JOSE, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company, whose mission is to revolutionize BPH treatment globally, announced today it will host an in-person investor …
Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) to be Presented at the National Kidney Foundation Spring Clinical Meetings
GlobeNewswire
·
April 10, 2025
WALTHAM, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today …